BRAFV600E mutation in Turkish patients with papillary thyroid cancer: Strong correlation with indicators of tumor aggressiveness

Endocrine

Volumn 42, Issue 2, 2012, Pages 404-410

  Kurtulmus, Neslihan ^a   Duren, Mete ^b   Ince, Umit ^c   Yakicier, M Cengiz ^c   Peker, Onder ^c   Aydin, Ozlem ^c   Altiok, Ender ^c   Giray, Serdar ^d   Azizlerli, Halil ^e  

^a Acibadem Maslak Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

^d Florence Nighthingale Hospital   (Turkey)

^e Macka Clinic   (Turkey)

Author keywords

Thyroid papillary cancer; Thyroid papillary carcinoma

Indexed keywords

B RAF KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER INVASION; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; TURKEY (REPUBLIC);

EID: 84867352088     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9651-x     Document Type: Article

References (41)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistcs. CA Cancer J. Clin. 60, 277-300 (2010)
2. Y.X. Wang, L. Zhao, X.Y. Wang, C.M. Liu, S.G. Yu, Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population. Endocrine (2011). doi:10.1007/s12020-011-9582-y
3. L. Pagano, M. Caputo, M.T. Samà, V. Garbaccio, M. Zavattaro, M.G. Mauri, F. Prodam, P. Marzullo, R. Boldorini, G. Valente, G. Aimaretti, Clinical-pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carità" in Novara. Endocrine (2012). doi:10.1007/s12020-012-9612-4
4. E.L. Mazzaferri, S.M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418-428 (1994)
5. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, S.I. Sherman, American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109-142 (2006)
6. P. Kaldrymides, I. Kostoglou-Athanassiou, A. Gkountouvas, E. Veniou, N. Ziras, Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature. Endocrine 37, 6-10 (2010)
7. M. Rivera, R.A. Ghossein, H. Schoder, D. Gomez, S.M. Larson, R.M. Tuttle, Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113, 48-56 (2008)
8. J.D. Lin, T.C. Chao, C. Hsueh, Clinical characteristics of poorly differentiated thyroid carcinomas compared with classical papillary thyroid carcinomas. Clin. Endocrinol. (Oxf.) 66, 224-228 (2007)
9. M.J. Robinson, M.H. Cobb, Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180-186 (1997)
10. E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, J.A. Fagin, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/ PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457 (2003)
11. R.M. Melillo, M.D. Castellone, V. Guarino, V. De Falco, A.M. Cirafici, G. Salvatore, F. Caiazzo, F. Basolo, R. Giannini, M. Kruhoffer, T. Orntoft, A. Fusco, M. Santoro, The RET/PTCRAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115, 1068-1081 (2005)
12. C. Peyssonnaux, A. Eychene, The The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 93, 53-62 (2001)
13. K.E. Mercer, C.A. Pritchard, Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653, 25-40 (2003)
14. M.J. Garnett, R. Marais, Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319 (2004)
15. R. Ciampi, Y.E. Nikiforov, RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148, 936-941 (2007)
16. M.N. Nikiforova, E.T. Kimura, M. Gandhi, P.W. Biddinger, J.A. Knauf, F. Basolo, Z. Zhu, R. Giannini, G. Salvatore, A. Fusco, M. Santoro, J.A. Fagin, Nikiforov YE.BRAF mutations in tumors are restricted to papillary carcinomas and anaplastic or poorly differantiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404 (2003)
17. M. Xing, BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005)
18. M. Xing, BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28, 742-762 (2007)
19. G. Riesco-Eizaguirre, I. Rodríguez, A. De la Vieja, E. Costamagna, N. Carrasco, M. Nistal, P. Santisteban, The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 69, 8317-8325 (2009)
20. C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, E. Tosi, A. Cavaliere, A. Gulino, S. Filetti, D. Russo, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92, 2840-2843 (2007)
21. C. Mian, S. Barollo, G. Pennelli, N. Pavan, M. Rugge, M.R. Pelizzo, R. Mazzarotto, D. Casara, D. Nacamulli, F. Mantero, G. Opocher, B. Busnardo, M.E. Girelli, Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin. Endocrinol. (Oxf.) 68, 108-116 (2008)
22. M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, K.J. Rhoden, K.A. Carson, V. Vasko, A. Larin, G. Tallini, S. Tolaney, E.H. Holt, P. Hui, C.B. Umbricht, S. Basaria, M. Ewertz, A.P. Tufaro, J.A. Califano, M.D. Ringel, M.A. Zeiger, D. Sidransky, P.W. Ladenson, BRAF mutation predicts a poorer clinical prognosis for papillar thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373-6379 (2005)
23. R. Elisei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Giannini, C. Romei, P. Miccoli, A. Pinchera, Basolo F BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93, 3943-3949 (2008)
24. UICC, in TNM Classification of Malignant Tumors, 6th edn., ed. by L.H. Sobin, C.H. Wittekind (Wiles-Liss, New York, 2002)
25. L.R. Rowe, B.G. Bentz, J.S. Bentz, Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. CytoJournal 3, 10 (2006)
26. B. Stanojevic, R. Dzodic, V. Saenko, Z. Milovanovic, G. Pupic, O. Zivkovic, I. Markovic, I. Djurisic, M. Buta, B. Dimitrijevic, T. Rogounovitch, N. Mitsutake, M. Mine, Y. Shibata, M. Nakashima, S. Yamashita, Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr. J. 58, 381-393 (2011)
27. V. Trovisco, P. Soares, M. Sobrinho-Simoes, B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum. Pathol. 37, 781-786 (2006)
28. X. Xu, R.M. Quiros, P. Gattuso, K.B. Ain, R.A. Prinz, High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 1, 4561-4567 (2003)
29. C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccoli, Basolo F Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92, 4085-4090 (2007)
30. Y. Ito, H. Yoshida, R. Maruo, S. Morita, T. Takano, M. Hirokawa, T. Yabuta, M. Fukushima, H. Inoue, C. Tomoda, M. Kihara, T. Uruno, T. Higashiyama, Y. Takamura, A. Miya, K. Kobayashi, F. Matsuzuka, A. Miyauchi, BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr. J. 56, 89-97 (2009)
31. A. Mathur, W. Moses, R. Rahbari, E. Khanafshar, Q.Y. Duh, O. Clark, E. Kebebew, Higher rate of BRAF mutation in papillary thyroid cancer over time: A single-institution study. Cancer 117, 4390-4395 (2011)
32. D. Ahn, J.S. Park, J.H. Sohn, J.H. Kim, S.K. Park, A.N. Seo, J.Y. Park, BRAF(V600E) mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 39, 198-203 (2012)
33. T.H. Kim, Y.J. Park, J.A. Lim, H.Y. Ahn, E.K. Lee, Y.J. Lee, K.W. Kim, S.K. Hahn, Y.K. Youn, K.H. Kim, B.Y. Cho, D.J. Park, The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer (2011). doi:10.1002/cncr.26500
34. F. Frasca, C. Nucera, G. Pellegriti, P. Gangemi, M. Attard, M. Stella, M. Loda, V. Vella, C. Giordano, F. Trimarchi, E. Mazzon,A. Belfiore, R. Vigneri, BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer 15, 191-205 (2008)
35. E. Kebebew, J. Weng, J. Bauer, G. Ranvier, O.H. Clark, Q.Y. Duh, D. Shibru, B. Bastian, A. Griffin, The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246, 466-471 (2007)
36. A. Czarniecka, D. Rusinek, E. Stobiecka, J. Krajewska, M. Kowal, A. Kropińska, J. Zebracka, M. Kowalska, J. Wloch, A. Maciejewski, D. Handkiewicz-Junak, Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. Endokrynol. Pol. 61, 462-466 (2010)
37. V. Trovisco, P. Soares, A. Preto, I.V. de Castro, J. Lima, P. Castro, V. Máximo, T. Botelho, S. Moreira, A.M. Meireles, J. Magalhães, A. Abrosimov, J. Cameselle-Teijeiro, M. Sobrinho-Simões, Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 446, 589-595 (2005)
38. L. Fugazzola, E. Puxeddu, N. Avenia, C. Romei, V. Cirello, A. Cavaliere, P. Faviana, D. Mannavola, S. Moretti, S. Rossi, M. Sculli, V. Bottici, P. Beck-Peccoz, F. Pacini, A. Pinchera, F. Santeusanio, R. Elisei, Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr. Relat. Cancer 13, 455-464 (2006)
39. G.M. Howell, S.E. Carty, M.J. Armstrong, S.O. Lebeau, S.P. Hodak, C. Coyne, M.T. Stang, K.L. McCoy, M.N. Nikiforova, Y.E. Nikiforov, L. Yip, Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann. Surg. Oncol. 19, 877-883 (2011)
40. L.A. Niemeier, H. Kuffner Akatsu, C. Song, S.E. Carty, S.P. Hodak, L. Yip, R.L. Ferris, G.C. Tseng, R.R. Seethala, S.O. Lebeau, M.T. Stang, C. Coyne, J.T. Johnson, A.F. Stewart, Y.E. Nikiforov, A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011). doi:10.1002/cncr.26425
41. Y.J. Park, Y.A. Kim, Y.J. Lee, S.H. Kim, S.Y. Park, K.W. Kim, J.K. Chung, Y.K. Youn, K.H. Kim, J. Park do, B.Y. Cho, Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E)mutation, clinicopathological features, and immunohistochemical findings. Head Neck 32, 38-45 (2010)